ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The introduction of (life-long) tyrosine kinase inhibitor treatment, which specifically targets BCR-ABL, often found in CML patients, likely also resulted in the high survival gains and favourable outcomes that were observed for all CML patients at AYA age in this study [9,13,63].